Thinking About Switching? Read Real Omnipod® Reviews from People Who Did
Switching diabetes technology isn’t a small decision.
Many people considering Omnipod tell us they ask the same questions:
- Will it fit my lifestyle?
- Is it complicated to use?
- What if it doesn’t work for me?
- Will I miss what I’m using now?
These stories come from people who asked those exact questions and decided to switch.
Featured Stories: Meet Sophie and Pete
“The word I’d use to describe Omnipod® is a game changer.
It’s given me a sense of independence back. It gives me more freedom and makes me feel more empowered when managing my diabetes.”
Sophie, Podder® since 2023
“Since I’ve been on the Omnipod 5, I can honestly say I’ve never had such a good night’s sleep. Sometimes I wake up in the morning and don’t even think to check my blood sugar levels"
Pete, Podder® since 2024
Experience Omnipod® for yourself
Take the first step toward tubeless, automated insulin delivery. Whether you want to try it, see it, or talk it through, there’s an option that works for you.
More stories about switching to Omnipod® 5
Switching from multiple daily injections
“There’s no worrying about daily injections I used to take. It’s giving me more time to focus on my family… it’s made me happier and healthier”
Richard, Podder® since 2024
Switching from a tubed pump
“I decided to switch to a tubeless pump because I liked the idea of not having to think about what I was wearing. The first thing I did was go travelling, and it was incredible. Literally, the whole not needing to unclip and unplug when you go into the shower, when you go into the sea, when you go into the pool. This is crazy”
Temi, Podder® since 2021
Switching as a parent or caregiver
“We were checking every couple of hours through the night, for a long time.
It wasn’t until we got Omnipod® 5 that we started sleeping for longer, and I had never had a full night’s sleep before that. Never.
Now, I feel like I can just be Lachlan’s mum. I don’t have to be his Type 1 mum”
Lesley (Lochlan’s Mum)
Omnipod® 5: Increase Time in Range1,2
& Simplify Life®
More time spent in range
Over 80% Time in Range with optimised settings.3
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
Helps correct highs and protect from low
Omnipod 5 automatically adjusts insulin delivery every 5 minutes day and night.
Supports a better quality of life
People using Omnipod 5 stress less about their diabetes.
Ready to explore Omnipod for yourself?
Take the first step toward tubeless, automated insulin delivery. Watch a live demo or try a demo Pod* to see how it could fit into your life.
* The demo Pod is a needle-free, non-functioning Pod. PDM/Controller is not included.
Thousands have already taken the next step
Head to our socials to explore real stories, see how Omnipod® fits into everyday life, and understand what it’s really like to make the change.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs 29.7%, P<0.0001, respectively. Mean time in hypoglycaemic range in adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3- mo Omnipod 5 = 1.32%, P<0.0001. Mean time in hypoglycaemic range in children (<3.9 mmol/L or <70mg/dL as measured by CGM): ST = 2.21%, 3-mo Omnipod 5 = 1.78%, P<0.0456.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3- month AID phase with Omnipod 5 system. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9mmol/L or <70mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3- month AID phase with Omnipod 5 system. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9mmol/L or <70mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.